期刊文献+

病毒灭活血浆制备冷沉淀凝血因子的质量研究 被引量:9

Cryoprecipitate coagulation factor prepared by virus inactivated plasma
下载PDF
导出
摘要 目的:通过对以病毒灭活血浆为原料制备的冷沉淀凝血因子的含量和活性进行检测,分析其可行性,并为进一步提高输血安全提供依据。方法:联袋常规采集血液100袋(400mL/袋),分离出血浆(200mL/袋)后每袋平均分为两袋,分别作为对照组新鲜冰冻血浆和实验组病毒灭活血浆。两组血浆制备后分别提取冷沉淀凝血因子速冻保存备用,测定其相关指标。结果:实验组(病毒灭活血浆)血浆凝血因子Ⅱ、Ⅴ、ⅤⅡ、ⅤⅢ、ⅠX、X低于对照组(新鲜冰冻血浆),差异均有统计学意义(P<0.01),纤维蛋白原(Fg)无统计学差异(P>0.05);实验组血浆凝血酶原时间(PT)、凝血酶时间(TT)与对照组差异无统计学意义(P>0.05),活化部分凝血酶原时间(APTT)高于对照组,差异有统计学意义(P<0.01);实验组血浆球蛋白(G)低于对照组、A/G高于对照组,与对照组差异有统计学意义(P<0.01),总蛋白(TP)、白蛋白(ALB)无统计学差异(P>0.05)。结论:病毒灭活技术对血液中的有效成分产生不同程度的损伤,除凝血因子FⅧ和FⅨ以外(小于70%),其余在可接受的范围内。 Objective: To investigate the effect of plasma viral inactivation on the activity of main coagulation factors, and the feasibility for preparation of cryoprecipitate with viral inactivation plasma. Methods. A total of 100 prepared plasma were equally splited into two aliquots, experimental group (virus inactivated blood plasma) and control group (fresh frozen plasma). Variables of two groups were compared. Results: The difference of FⅡ,Ⅴ,Ⅶ, Ⅷ, Ⅸ, Ⅹ ,G, A/G and APTT were significant between the two groups (P〈0. 01). In the experimental group plasma PTTT there was no statistically sig- nificant difference in Fg, PT, TT, TP, or ALB compared with the control group. Conclusions:Virus inactivated technology produce different degrees of damage to the effective components in the blood, besides clotting factor FⅧ and FIX (〈70%), and the rest is in the acceptable range.
出处 《海南医学院学报》 CAS 2014年第5期707-709,共3页 Journal of Hainan Medical University
基金 广州市番禺区科技项目(2012-Z-03-53)~~
关键词 病毒灭活 冷沉淀 凝血因子 Virus inactivation Cryoprecipitate Coagulation factor
  • 相关文献

参考文献10

  • 1杨夏,翟春燕,白旭华.病毒灭活血浆亚甲蓝含量的检测及质量控制[J].中国输血杂志,2011,24(10):881-883. 被引量:8
  • 2高丽,任少敏,刘彩.亚甲蓝光化学法病毒灭活血浆的质量控制措施[J].中国误诊学杂志,2011,11(24):5898-5898. 被引量:2
  • 3Wagner SJ. Virus inactivation in blood components by photoactive phenothiazine dyes[J]. Transfus Med, 2002, 16(1) :61-66.
  • 4Richard K,Spence MD. FACS. Clinical use of plasma and plasma fractions[J]. Best Practice & Research Clinical Haematology,2006,19(1) : 83-96.
  • 5Kim IS, Choi YW, Kang Y, et al. Dry-heat treatment process forenhancing viral safety of an antihemophilic factor V Ⅲ concentrateprepared from human plasma [J]. World Journal of Microbiology and Biotechnology, 2008, 20(1): 81-83.
  • 6Hellstern P, Bach J, Haubelt H, et al. The impact of the intensity of serial automated plasmapheresis and the speed of deep-freezing on the quality of plasma[J]. Transfusion . 2001,12 (2) :149-155.
  • 7Omidkhoda A,, Tabatabaei MR, Atarodi K, et al. A comparative studyof the effects of temperature, time and factor V Ⅲ assay type on factorV Ⅲ activity in cryoprecipitate in Iran[J]. Blood Transfus, 2011, 163 (3) :407-414.
  • 8Heger A, Svae TE, Neisser-Svae A, et al. Bioehemi- calquality of the pharmaceutically licensed plasma Oc- taplasLG afterimplementation of a novel prion protein (PrPSc) removal technologyand reduction of the sol- vent/detergent(S/D) process time[J]. Vox Sanguinis , 2009, 105: 1387-1393.
  • 9Scott E,Puae K , Heraly J, et al. Wvaluation and com- parison of coagulation factor activity in fresh-frozen plasma and 24-hour plasma at thaw and after 120 hours of i to 6℃ storage[J]. Transfusion, 2009,49(8) : 1584-1591.
  • 10黄文杰,范恩勇,孙海英,纪燕,郭铭华,王爱华,周健.亚甲蓝光化学法病毒灭活血浆对凝血因子的影响[J].实用医学杂志,2006,22(18):2193-2194. 被引量:21

二级参考文献15

共引文献27

同被引文献106

引证文献9

二级引证文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部